Dexrazoxane Hydrochloride Patent Expiration
Dexrazoxane Hydrochloride is Used for managing extravasation caused by IV anthracycline chemotherapy. It was first introduced by Pfizer Inc
Dexrazoxane Hydrochloride Patents
Given below is the list of patents protecting Dexrazoxane Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Totect | US6727253 | Treatment of accidental extravasation of anthracyclines |
Mar 13, 2020
(Expired) | Clinigen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dexrazoxane Hydrochloride's patents.
Latest Legal Activities on Dexrazoxane Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Dexrazoxane Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail-Petition Decision - Dismissed Critical | 05 Oct, 2016 | US6727253 |
| Petition Decision - Dismissed Critical | 05 Oct, 2016 | US6727253 |
| Petition Entered | 04 Apr, 2016 | US6727253 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Sep, 2013 | US6727253 |
| Correspondence Address Change Critical | 16 Sep, 2013 | US6727253 |
| Recordation of Patent Grant Mailed Critical | 27 Apr, 2004 | US6727253 |
| Patent Issue Date Used in PTA Calculation Critical | 27 Apr, 2004 | US6727253 |
| Issue Notification Mailed Critical | 08 Apr, 2004 | US6727253 |
| Receipt into Pubs | 18 Mar, 2004 | US6727253 |
| Application Is Considered Ready for Issue Critical | 17 Mar, 2004 | US6727253 |
Dexrazoxane Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Dexrazoxane Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Dexrazoxane Hydrochloride. The first generic version for Dexrazoxane Hydrochloride was by Hikma Pharmaceuticals Usa Inc and was approved on Sep 28, 2004. And the latest generic version is by Gland Pharma Ltd and was approved on Dec 16, 2019.
Given below is the list of companies who have filed for Dexrazoxane Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 2 different strengths of generic version for Dexrazoxane Hydrochloride. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 250MG BASE/VIAL
(reference standard) | injectable | Prescription | INJECTION | AP | Oct 19, 2011 |
| EQ 500MG BASE/VIAL
(reference standard) | injectable | Prescription | INJECTION | AP | Oct 19, 2011 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
2. GLAND
Gland Pharma Ltd has filed for 2 different strengths of generic version for Dexrazoxane Hydrochloride. Given below are the details of the strengths of this generic introduced by Gland.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Nov 28, 2016 |
| EQ 250MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Dec 16, 2019 |
Manufacturing Plant Locations New
Gland's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Gland as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
3. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Dexrazoxane Hydrochloride. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Sep 28, 2004 |
| EQ 250MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Sep 28, 2004 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||